Nuvalent (NUVL) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Company strategy and vision

• Focuses on structure-based drug design targeting clinically validated kinases, aiming to address unmet needs in oncology through innovative chemistry.

• Building a global, sustainable biotech company by developing, discovering, and delivering drugs, with a vision to expand beyond current lead programs.

• Transitioned from seeking ex-US partners to independently building global commercial infrastructure, citing flexibility and market opportunity.

• Actively recruiting talent and building international capabilities to support global launches.

Pipeline progress and regulatory milestones

• NDA for zidesamtinib (ROS1 inhibitor) in TKI-pretreated NSCLC accepted by FDA, with a PDUFA date of September 18 and US commercial launch preparations underway.

• Plans to submit data for TKI-naive ROS1 indication expansion in the second half of the year.

• NDA for NVL-655 (ALK inhibitor) in TKI-pretreated NSCLC on track for submission in the first half of the year; phase 3 ALCAZAR study ongoing in TKI-naive ALK.

• Advancing HER2 exon 20 phase 1b/2 study in HER2-altered NSCLC, with new development candidate disclosure expected by year-end.

Product differentiation and clinical data

• Zidesamtinib uniquely targets ROS1 fusions and mutations, penetrates the CNS, and demonstrates high CNS complete response rates, differentiating it from competitors.

• NVL-655 shows durable responses in ALK-positive NSCLC, including activity beyond lorlatinib and strong CNS efficacy, supporting a broad label submission.

• Safety profile for NVL-655 includes manageable transaminase elevations, with protocol adjustments to minimize premature discontinuation.

• HER2 program aims for strong selectivity, CNS penetration, and broad applicability across solid tumors, with initial data and future directions to be disclosed.